Recombinant factor IX biobetter - UBI Pharma
Alternative Names: UB-854Latest Information Update: 17 Jan 2024
At a glance
- Originator UBI Pharma
- Class Antihaemorrhagics; Blood coagulation factors; Recombinant proteins
- Mechanism of Action Blood coagulation factor replacements; Factor IX replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Haemophilia B
Most Recent Events
- 20 Dec 2023 Early research in Haemophilia B in Taiwan (Parenteral) (UBI Pharma pipeline, December 2023)